iBio Strengthens Board with Appointment of Two New Independent Directors
November 25, 2024 08:00 ET
|
iBio, Inc.
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David...
iBio Reports Fiscal First Quarter 2025 Financial Results
November 12, 2024 16:05 ET
|
iBio, Inc.
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its...
iBio and AstralBio Provide Update on Myostatin Program for Obesity
October 10, 2024 08:00 ET
|
iBio, Inc.
SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for...
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
September 20, 2024 16:05 ET
|
iBio, Inc.
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended...
iBio to Participate in Upcoming Investor Conferences
September 03, 2024 07:00 ET
|
iBio, Inc.
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin...
iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development
August 12, 2024 16:30 ET
|
iBio, Inc.
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of Kristi Sarno as senior vice...
iBio Closes Sale of Manufacturing Facility in Texas
June 03, 2024 07:00 ET
|
iBio, Inc.
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) --...
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024 16:05 ET
|
iBio, Inc.
Strengthened cash position with investment by healthcare specialist investorsExpanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 ...
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
March 27, 2024 07:00 ET
|
iBio, Inc.
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover,...
iBio Announces $15.0 Million Private Placement
March 26, 2024 19:35 ET
|
iBio, Inc.
– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an...